<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=1200, user-scalable=yes, initial-scale=0.4, minimum-scale=0.1">
    <title>Codeine - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
        
        // Force desktop behavior by overriding mobile detection
        window.isMobile = false;
        window.isDesktop = true;
        
        // Override any mobile detection functions
        if (window.matchMedia) {
            const originalMatchMedia = window.matchMedia;
            window.matchMedia = function(query) {
                // Force desktop media queries to always match for min-width
                // and mobile queries to never match
                if (query.includes('max-width') && (query.includes('768px') || query.includes('480px'))) {
                    return { matches: false, addListener: function() {}, removeListener: function() {} };
                }
                if (query.includes('min-width')) {
                    return { matches: true, addListener: function() {}, removeListener: function() {} };
                }
                return originalMatchMedia.call(this, query);
            };
        }
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/depressants/">Depressants</a> ‚ÜÅE<span>Codeine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Codeine</h1>
        <h2 class="chemical-name">Codeine phosphate</h2>
         <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Codeine" 
                data-category="Depressants" 
                data-chemical="Codeine phosphate">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Forms</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Generic Names</h4>
              <span>Codeine</span> ‚Ä¢ <span>Codeine phosphate</span> ‚Ä¢ <span>Codeine sulfate</span> ‚Ä¢ <span>Methylmorphine</span>
            </div>
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Tylenol #3</span> ‚Ä¢ <span>Robitussin AC</span> ‚Ä¢ <span>Fioricet with Codeine</span> ‚Ä¢ <span>Promethazine-Codeine</span>
            </div>
            <div class="name-category">
              <h4>Combination Products</h4>
              <span>Codeine + Acetaminophen</span> ‚Ä¢ <span>Codeine + Aspirin</span> ‚Ä¢ <span>Codeine + Promethazine</span> ‚Ä¢ <span>Co-codamol</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Lean</span> ‚Ä¢ <span>Purple Drank</span> ‚Ä¢ <span>Sizzurp</span> ‚Ä¢ <span>T3s</span> ‚Ä¢ <span>Captain Cody</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status prescription">Prescription</span>
          <span class="duration medium">3-6 hours</span>
          <span class="natural">Natural</span>
          <span class="addiction-risk moderate">Moderate Risk</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/codeine.jpg" alt="Codeine tablets, cough syrup bottles, prescription pills, and molecular structure diagram" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇàH‚ÇÇ‚ÇÅNO‚ÇÅE/p>
            <p>MW: 299.36 g/mol</p>
            <p>Natural opium alkaloid</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pharmaceutical-forms">
          <h4>Pharmaceutical Preparations</h4>
          <ul>
            <li><strong>Tablets:</strong> White, round or oblong, various strengths and imprints</li>
            <li><strong>Oral solutions:</strong> Clear to amber liquid, sweet taste</li>
            <li><strong>Injectable:</strong> Clear sterile solution for medical use</li>
            <li><strong>Suppositories:</strong> Rectal administration for specific indications</li>
            <li><strong>Extended-release:</strong> Long-acting formulations for chronic pain</li>
          </ul>
        </div>
        
        <div class="standard-preparations">
          <h4>Standard Dosage Forms</h4>
          <div class="preparation-type">
            <h5>üíä Codeine Monotherapy</h5>
            <ul>
              <li><strong>Tablets:</strong> 15mg, 30mg, 60mg</li>
              <li><strong>Oral solution:</strong> 15mg/5ml, 30mg/5ml</li>
              <li><strong>Injectable:</strong> 30mg/ml, 60mg/ml</li>
              <li><strong>Suppositories:</strong> 30mg, 60mg</li>
            </ul>
          </div>
          
          <div class="preparation-type">
            <h5>ü§ÅECombination Products</h5>
            <ul>
              <li><strong>Tylenol #3:</strong> 30mg codeine + 300mg acetaminophen</li>
              <li><strong>Tylenol #4:</strong> 60mg codeine + 300mg acetaminophen</li>
              <li><strong>Co-codamol:</strong> 8mg, 15mg, 30mg codeine + paracetamol</li>
              <li><strong>Aspirin + Codeine:</strong> 30mg codeine + 325mg aspirin</li>
            </ul>
          </div>
          
          <div class="preparation-type">
            <h5>üçØ Cough Syrups</h5>
            <ul>
              <li><strong>Robitussin AC:</strong> 10mg codeine per 5ml + guaifenesin</li>
              <li><strong>Promethazine-Codeine:</strong> 10mg codeine + 6.25mg promethazine per 5ml</li>
              <li><strong>Plain codeine syrup:</strong> 15mg/5ml or 30mg/5ml</li>
              <li><strong>Pediatric formulations:</strong> Lower concentrations for children</li>
            </ul>
          </div>
        </div>
        
        <div class="lean-identification">
          <h4>üçá "Lean" / Purple Drank Preparation</h4>
          <ul>
            <li><strong>Base ingredient:</strong> Promethazine-codeine cough syrup</li>
            <li><strong>Mixer:</strong> Sprite, 7-Up, or other clear sodas</li>
            <li><strong>Color:</strong> Purple hue from promethazine syrup</li>
            <li><strong>Consistency:</strong> Thick, syrupy texture when mixed</li>
            <li><strong>Cultural context:</strong> Hip-hop culture popularization</li>
            <li><strong>Slang terms:</strong> Lean, sizzurp, purple drank, dirty sprite</li>
          </ul>
        </div>
        
        <div class="abuse-forms">
          <h4>üíä Abuse & Diversion Forms</h4>
          <ul>
            <li><strong>Cold water extraction:</strong> Separating codeine from acetaminophen</li>
            <li><strong>Prescription shopping:</strong> Multiple prescriptions from different doctors</li>
            <li><strong>Internet pharmacy:</strong> Online prescription sources</li>
            <li><strong>Theft/diversion:</strong> Stolen from pharmacies or patients</li>
            <li><strong>Fake prescriptions:</strong> Forged or altered prescriptions</li>
          </ul>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      
      <div class="dosage-warning medical">
        <h4>üè• PRESCRIPTION MEDICATION</h4>
        <p><strong>Medical use only:</strong> Codeine is a prescription opioid that should only be used under medical supervision. Self-medication carries addiction and overdose risks, especially with combination products containing acetaminophen.</p>
      </div>

      <div class="dosage-by-indication">
        <h4>Medical Dosage Guidelines</h4>
        
        <div class="dosage-indication">
          <h5>üè• Pain Management</h5>
          <div class="dose-range medical">
            <span class="range-label">Mild pain (adult)</span>
            <span class="dose-amount">15-30mg q4-6h</span>
          </div>
          <div class="dose-range medical">
            <span class="range-label">Moderate pain (adult)</span>
            <span class="dose-amount">30-60mg q4-6h</span>
          </div>
          <div class="dose-range medical">
            <span class="range-label">Maximum daily</span>
            <span class="dose-amount">240mg</span>
          </div>
        </div>

        <div class="dosage-indication">
          <h5>ü§ß Cough Suppression</h5>
          <div class="dose-range medical">
            <span class="range-label">Adult antitussive</span>
            <span class="dose-amount">10-20mg q4-6h</span>
          </div>
          <div class="dose-range medical">
            <span class="range-label">Pediatric (>12 years)</span>
            <span class="dose-amount">5-10mg q4-6h</span>
          </div>
          <div class="dose-range medical">
            <span class="range-label">Maximum daily (cough)</span>
            <span class="dose-amount">120mg</span>
          </div>
        </div>

        <div class="dosage-indication">
          <h5>‚ö†ÔøΩEÔøΩERecreational/Abuse Dosing</h5>
          <div class="dose-range threshold">
            <span class="range-label">Threshold</span>
            <span class="dose-amount">30-60mg</span>
          </div>
          <div class="dose-range light">
            <span class="range-label">Light</span>
            <span class="dose-amount">60-90mg</span>
          </div>
          <div class="dose-range common">
            <span class="range-label">Common</span>
            <span class="dose-amount">90-150mg</span>
          </div>
          <div class="dose-range dangerous">
            <span class="range-label">High risk</span>
            <span class="dose-amount">200mg+</span>
          </div>
        </div>
      </div>
      
      <div class="cyp2d6-genetics">
        <h4>üß¨ CYP2D6 Genetic Variations</h4>
        <ul>
          <li><strong>Ultra-rapid metabolizers (~3-5%):</strong> Convert codeine to morphine very quickly - overdose risk</li>
          <li><strong>Extensive metabolizers (~77%):</strong> Normal codeine conversion and effects</li>
          <li><strong>Intermediate metabolizers (~10-15%):</strong> Reduced codeine conversion, less effective</li>
          <li><strong>Poor metabolizers (~5-10%):</strong> Little to no morphine conversion, minimal effects</li>
          <li><strong>Clinical significance:</strong> Genetic testing can predict response and safety</li>
          <li><strong>Ethnic variations:</strong> Different frequencies across populations</li>
        </ul>
      </div>

      <div class="combination-warnings">
        <h4>‚ö†ÔøΩEÔøΩECombination Product Warnings</h4>
        <ul>
          <li><strong>Acetaminophen toxicity:</strong> Liver damage at >4g/day - major concern with abuse</li>
          <li><strong>Aspirin bleeding:</strong> GI bleeding risk, especially with alcohol</li>
          <li><strong>Promethazine potentiation:</strong> Enhanced sedation and respiratory depression</li>
          <li><strong>Cold water extraction:</strong> Dangerous amateur chemistry to separate codeine</li>
          <li><strong>Maximum safe limits:</strong> Consider all ingredients, not just codeine</li>
        </ul>
      </div>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral Administration)</h4>
        <div class="timeline-item">
          <span class="time">T+0:15-0:45</span>
          <span class="effect">Onset - mild euphoria, cough suppression</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:45-2:00</span>
          <span class="effect">Peak - maximum analgesia, mood lift, sedation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-4:00</span>
          <span class="effect">Plateau - sustained effects, drowsiness</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Comedown - gradual return, possible rebound symptoms</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category therapeutic">
          <h4>‚úÅETherapeutic Effects</h4>
          <ul>
            <li>Effective cough suppression (antitussive)</li>
            <li>Mild to moderate pain relief</li>
            <li>Reduced anxiety in pain/illness context</li>
            <li>Improved sleep in symptomatic patients</li>
            <li>Diarrhea control (constipating effect)</li>
            <li>Functional improvement in chronic pain</li>
            <li>Less respiratory depression than morphine</li>
          </ul>
        </div>
        
        <div class="effect-category recreational">
          <h4>üåü Recreational Effects</h4>
          <ul>
            <li>Mild euphoria and mood elevation</li>
            <li>Warm, comfortable sensations</li>
            <li>Relaxation and stress relief</li>
            <li>Emotional numbing/detachment</li>
            <li>Dreamy, floaty feelings</li>
            <li>Reduced anxiety and worry</li>
            <li>Pleasant drowsiness</li>
            <li>Social disinhibition (mild)</li>
          </ul>
        </div>

        <div class="effect-category negative">
          <h4>‚ùÅEAdverse Effects</h4>
          <ul>
            <li>Nausea and vomiting (especially higher doses)</li>
            <li>Constipation (common with regular use)</li>
            <li>Drowsiness and cognitive impairment</li>
            <li>Dizziness and lightheadedness</li>
            <li>Dry mouth and dehydration</li>
            <li>Urinary retention</li>
            <li>Respiratory depression (high doses)</li>
            <li>Histamine release (itching, rash)</li>
          </ul>
        </div>

        <div class="effect-category withdrawal">
          <h4>üîÑ Withdrawal Effects</h4>
          <ul>
            <li><strong>Early (8-24 hours):</strong> Anxiety, restlessness, cravings</li>
            <li><strong>Peak (24-72 hours):</strong> Muscle aches, runny nose, insomnia</li>
            <li><strong>Physical symptoms:</strong> Sweating, goosebumps, diarrhea, tearing</li>
            <li><strong>Psychological:</strong> Depression, irritability, drug craving</li>
            <li><strong>Duration:</strong> Acute phase 5-7 days, milder than stronger opioids</li>
            <li><strong>Rebound symptoms:</strong> Return of original pain/cough</li>
          </ul>
        </div>
      </div>

      <div class="lean-culture">
        <h4>üçá "Lean" Culture & Effects</h4>
        <div class="lean-aspects">
          <div class="lean-aspect">
            <h5>Cultural Context</h5>
            <ul>
              <li><strong>Hip-hop influence:</strong> Popularized by Southern rap artists</li>
              <li><strong>Social drinking:</strong> Consumed as recreational beverage</li>
              <li><strong>Status symbol:</strong> Expensive prescription syrup as luxury</li>
              <li><strong>Ritual consumption:</strong> Specific preparation and serving methods</li>
            </ul>
          </div>
          
          <div class="lean-aspect">
            <h5>Enhanced Effects</h5>
            <ul>
              <li><strong>Promethazine synergy:</strong> Enhanced sedation and euphoria</li>
              <li><strong>Sugar potentiation:</strong> Soda sugar may enhance absorption</li>
              <li><strong>Prolonged consumption:</strong> Sipping slowly extends duration</li>
              <li><strong>Social reinforcement:</strong> Group consumption increases appeal</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Codeine is a naturally occurring opioid alkaloid that acts as a prodrug requiring metabolic conversion to morphine for primary analgesic effects. It binds directly to mu-opioid receptors with low affinity, but its therapeutic effects primarily result from CYP2D6-mediated O-demethylation to morphine. This conversion explains both its moderate potency and significant inter-individual variability in response based on genetic polymorphisms.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œº-opioid receptors (MOR)</strong></span>
            <span class="affinity">Low affinity (codeine), high affinity (morphine metabolite)</span>
            <span class="function">Primary analgesia, mild euphoria, cough suppression</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ¥-opioid receptors (DOR)</strong></span>
            <span class="affinity">Very low affinity</span>
            <span class="function">Minimal contribution to analgesic effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ∫-opioid receptors (KOR)</strong></span>
            <span class="affinity">Negligible affinity</span>
            <span class="function">No significant interaction</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Cough reflex centers</strong></span>
            <span class="affinity">Direct suppression</span>
            <span class="function">Antitussive effects independent of analgesia</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary pathway:</strong> CYP2D6-mediated O-demethylation to morphine (~5-15%)</p>
          <p><strong>Secondary pathway:</strong> N-demethylation to norcodeine (inactive)</p>
          <p><strong>Conjugation:</strong> Glucuronidation to codeine-6-glucuronide (inactive)</p>
          <p><strong>Half-life:</strong> Codeine 2.5-4 hours, morphine 2-4 hours</p>
          <p><strong>Bioavailability:</strong> ~60-70% oral, ~100% parenteral</p>
          <p><strong>Peak plasma:</strong> 30-60 minutes oral, 10-30 minutes IV</p>
          <p><strong>Duration:</strong> 4-6 hours analgesic, 4-8 hours antitussive</p>
        </div>

        <h4>CYP2D6 Genetic Polymorphisms</h4>
        <div class="genetic-details">
          <h5>üß¨ Metabolizer Phenotypes</h5>
          <ul>
            <li><strong>Ultra-rapid metabolizers (UM):</strong> Gene duplications, excessive morphine production</li>
            <li><strong>Extensive metabolizers (EM):</strong> Normal enzyme function, standard response</li>
            <li><strong>Intermediate metabolizers (IM):</strong> Reduced enzyme activity, decreased efficacy</li>
            <li><strong>Poor metabolizers (PM):</strong> Minimal enzyme function, little therapeutic effect</li>
          </ul>
          
          <h5>üåç Ethnic Distribution</h5>
          <ul>
            <li><strong>Caucasians:</strong> ~7% PM, ~1-2% UM</li>
            <li><strong>East Asians:</strong> ~1% PM, rare UM</li>
            <li><strong>Africans:</strong> ~2% PM, ~29% UM (some populations)</li>
            <li><strong>Middle Eastern:</strong> Variable, up to 10% UM in some groups</li>
          </ul>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Prodrug nature:</strong> Requires metabolic activation for full effects</li>
          <li><strong>Antitussive selectivity:</strong> Cough suppression at lower doses than analgesia</li>
          <li><strong>Ceiling effect:</strong> Limited respiratory depression compared to morphine</li>
          <li><strong>Histamine release:</strong> Causes itching and potential allergic reactions</li>
          <li><strong>Natural alkaloid:</strong> Found in opium poppy alongside morphine</li>
          <li><strong>OTC availability:</strong> Low-dose formulations available without prescription in some countries</li>
        </ul>

        <h4>Tolerance & Dependence</h4>
        <div class="dependence-mechanisms">
          <h5>üß† Tolerance Development</h5>
          <ul>
            <li><strong>Receptor tolerance:</strong> Mu-opioid receptor downregulation with chronic use</li>
            <li><strong>Metabolic tolerance:</strong> Potential CYP2D6 induction with repeated dosing</li>
            <li><strong>Timeline:</strong> Noticeable tolerance within 1-2 weeks of regular use</li>
            <li><strong>Cross-tolerance:</strong> Complete with other mu-opioid agonists</li>
            <li><strong>Antitussive tolerance:</strong> May develop separately from analgesic tolerance</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Safety Warnings</h4>
          <ul>
            <li><strong>Acetaminophen toxicity:</strong> Liver damage/failure with combination products</li>
            <li><strong>Respiratory depression:</strong> Especially dangerous in ultra-rapid metabolizers</li>
            <li><strong>Physical dependence:</strong> Develops within 1-2 weeks of regular therapeutic use</li>
            <li><strong>Driving impairment:</strong> Significant cognitive and motor impairment</li>
            <li><strong>Pediatric risks:</strong> Enhanced sensitivity, respiratory depression in children</li>
          </ul>
        </div>
        
        <div class="safety-item genetic">
          <h4>üß¨ Genetic Risk Factors</h4>
          <ul>
            <li><strong>Ultra-rapid metabolizers:</strong> Potentially fatal morphine accumulation</li>
            <li><strong>Breastfeeding mothers:</strong> UM mothers can transfer dangerous morphine levels</li>
            <li><strong>Poor metabolizers:</strong> Ineffective treatment, may seek higher doses</li>
            <li><strong>Genetic testing:</strong> CYP2D6 testing available to predict response</li>
            <li><strong>Drug interactions:</strong> CYP2D6 inhibitors affect conversion</li>
          </ul>
        </div>
        
        <div class="safety-item harm-reduction">
          <h4>üõ°ÔøΩEÔøΩEHarm Reduction Strategies</h4>
          <ul>
            <li><strong>Prescription adherence:</strong> Follow prescribed dosing schedules exactly</li>
            <li><strong>Avoid alcohol:</strong> Dangerous respiratory depression synergy</li>
            <li><strong>Monitor acetaminophen:</strong> Track total daily intake from all sources</li>
            <li><strong>Genetic awareness:</strong> Be alert for unusual sensitivity or lack of effect</li>
            <li><strong>Gradual tapering:</strong> Reduce dose slowly to prevent withdrawal</li>
            <li><strong>Medical supervision:</strong> Regular monitoring for dependence signs</li>
          </ul>
        </div>
      </div>

      <div class="combination-safety">
        <h4>üíä Combination Product Safety</h4>
        <div class="combination-risks">
          <h5>Acetaminophen Combinations</h5>
          <ul>
            <li><strong>Hepatotoxicity:</strong> >4g acetaminophen daily causes liver damage</li>
            <li><strong>Alcohol interaction:</strong> Increased liver toxicity risk</li>
            <li><strong>Chronic use:</strong> Lower threshold for toxicity with regular use</li>
            <li><strong>Cold water extraction:</strong> Dangerous amateur separation attempts</li>
          </ul>
        </div>
        
        <div class="combination-risks">
          <h5>Promethazine Combinations ("Lean")</h5>
          <ul>
            <li><strong>Enhanced sedation:</strong> Dangerous respiratory depression</li>
            <li><strong>Anticholinergic effects:</strong> Dry mouth, urinary retention, confusion</li>
            <li><strong>Cardiac risks:</strong> QT prolongation, arrhythmias</li>
            <li><strong>Temperature regulation:</strong> Impaired thermoregulation</li>
          </ul>
        </div>
      </div>

      <div class="overdose-recognition">
        <h4>üöë Overdose Recognition & Response</h4>
        <div class="overdose-signs">
          <h5>Signs of Codeine Overdose</h5>
          <ul>
            <li><strong>Respiratory:</strong> Slow, shallow breathing or respiratory arrest</li>
            <li><strong>Consciousness:</strong> Extreme drowsiness progressing to coma</li>
            <li><strong>Physical:</strong> Pinpoint pupils, cold/clammy skin, weak pulse</li>
            <li><strong>Color changes:</strong> Blue lips, fingernails, skin (cyanosis)</li>
            <li><strong>Combination toxicity:</strong> Additional symptoms from acetaminophen/other drugs</li>
          </ul>
        </div>
        
        <div class="overdose-response">
          <h5>Emergency Response Protocol</h5>
          <ul>
            <li><strong>Call emergency services:</strong> Immediate medical attention required</li>
            <li><strong>Naloxone administration:</strong> Give Narcan if available - may need multiple doses</li>
            <li><strong>Airway management:</strong> Position for breathing, rescue breathing if needed</li>
            <li><strong>Monitor closely:</strong> Codeine/morphine effects last longer than naloxone</li>
            <li><strong>Hospital evaluation:</strong> Combination overdose may require additional treatment</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous Combinations</h4>
          <ul>
            <li><strong>CNS depressants:</strong> Alcohol, benzodiazepines, barbiturates - respiratory depression</li>
            <li><strong>MAOIs:</strong> Potential serotonin syndrome, CNS excitation</li>
            <li><strong>Multiple opioids:</strong> Additive respiratory depression, overdose risk</li>
            <li><strong>Muscle relaxants:</strong> Enhanced sedation, respiratory compromise</li>
            <li><strong>Sleep medications:</strong> Dangerous CNS depression</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High-Risk Combinations</h4>
          <ul>
            <li><strong>Antihistamines:</strong> Increased sedation, anticholinergic effects</li>
            <li><strong>Antidepressants:</strong> Variable interactions, enhanced sedation</li>
            <li><strong>Anticonvulsants:</strong> Altered metabolism, enhanced CNS depression</li>
            <li><strong>Beta-blockers:</strong> Enhanced cardiovascular depression</li>
            <li><strong>Diuretics:</strong> Increased risk of urinary retention</li>
          </ul>
        </div>
        
        <div class="interaction cyp2d6">
          <h4>üß¨ CYP2D6 Metabolic Interactions</h4>
          <ul>
            <li><strong>CYP2D6 inhibitors:</strong> Quinidine, fluoxetine, paroxetine - reduced morphine conversion</li>
            <li><strong>CYP2D6 inducers:</strong> Rifampin, dexamethasone - enhanced metabolism</li>
            <li><strong>Competing substrates:</strong> Other CYP2D6 drugs may reduce codeine effectiveness</li>
            <li><strong>Clinical significance:</strong> Can dramatically alter therapeutic response</li>
          </ul>
        </div>
        
        <div class="interaction acetaminophen">
          <h4>üíä Acetaminophen Combination Interactions</h4>
          <ul>
            <li><strong>Alcohol:</strong> Increased hepatotoxicity, liver damage risk</li>
            <li><strong>Warfarin:</strong> Enhanced anticoagulation, bleeding risk</li>
            <li><strong>Other acetaminophen:</strong> Cumulative hepatotoxicity from multiple sources</li>
            <li><strong>Hepatotoxic drugs:</strong> Additive liver damage potential</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p><strong>Schedule II/III</strong> - Pure codeine Schedule II, combinations Schedule III. Prescription required for most formulations.</p>
            <p><strong>OTC availability:</strong> Some low-dose cough syrups available OTC in certain states</p>
            <p><strong>DEA monitoring:</strong> Prescription monitoring programs track dispensing</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p><strong>Class B</strong> - Up to 5 years for possession, 14 years for supply when pure.</p>
            <p><strong>Pharmacy medicines:</strong> Low-dose combinations available from pharmacies</p>
            <p><strong>Prescription monitoring:</strong> NHS monitoring for abuse patterns</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Canada</h4>
            <p><strong>Controlled substance</strong> - Prescription required, OTC exemptions for low doses.</p>
            <p><strong>Tylenol #1:</strong> Available OTC with 8mg codeine + acetaminophen + caffeine</p>
          </div>
          <div class="jurisdiction">
            <h4>üåç International Variations</h4>
            <p><strong>Wide variation:</strong> Some countries allow OTC access, others strict prescription only</p>
            <p><strong>UN Single Convention:</strong> Internationally controlled substance</p>
            <p><strong>Cultural differences:</strong> Different attitudes toward cough medicine access</p>
          </div>
        </div>
        
        <div class="prescription-monitoring">
          <h4>üìã Prescription Monitoring</h4>
          <ul>
            <li><strong>PDMP systems:</strong> Electronic monitoring of controlled substance prescriptions</li>
            <li><strong>Doctor shopping:</strong> Detection of patients seeking multiple prescriptions</li>
            <li><strong>Quantity limits:</strong> Insurance and regulatory limits on monthly supplies</li>
            <li><strong>Prior authorization:</strong> Insurance requirements for higher doses or quantities</li>
            <li><strong>Abuse deterrent:</strong> Combination formulations to reduce extraction</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Medical Development</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1832</span>
          <p>First isolated from opium by French chemist Pierre-Jean Robiquet</p>
        </div>
        <div class="history-event">
          <span class="year">1850s</span>
          <p>Chemical structure determined, methylmorphine relationship identified</p>
        </div>
        <div class="history-event">
          <span class="year">1914</span>
          <p>Harrison Narcotics Tax Act includes codeine regulation</p>
        </div>
        <div class="history-event">
          <span class="year">1950s</span>
          <p>Combination products with acetaminophen widely introduced</p>
        </div>
        <div class="history-event">
          <span class="year">1960s-70s</span>
          <p>Promethazine-codeine cough syrups become popular</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Hip-hop culture popularizes "lean" recreational use</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>CYP2D6 genetic variations discovered, clinical significance recognized</p>
        </div>
        <div class="history-event">
          <span class="year">2012</span>
          <p>FDA restricts pediatric use due to ultra-rapid metabolizer deaths</p>
        </div>
      </div>

      <div class="medical-development">
        <h4>üè• Medical & Cultural Evolution</h4>
        <div class="development-aspects">
          <div class="development-aspect">
            <h5>üß™ Pharmaceutical Innovation</h5>
            <p>Codeine became the foundation for numerous combination products, particularly with acetaminophen and aspirin. These combinations provided enhanced analgesia while attempting to reduce abuse potential through the inclusion of potentially hepatotoxic doses of acetaminophen.</p>
          </div>
          
          <div class="development-aspect">
            <h5>üéµ Cultural Impact</h5>
            <p>The transformation of prescription cough syrup into "lean" represents a unique cultural phenomenon where medical products became recreational drugs. Southern hip-hop culture, particularly artists from Houston, popularized this consumption method, leading to widespread recreational use.</p>
          </div>
          
          <div class="development-aspect">
            <h5>üß¨ Pharmacogenetic Revolution</h5>
            <p>Discovery of CYP2D6 genetic polymorphisms revolutionized understanding of codeine's variable effects. This led to personalized medicine approaches and recognition that "one size fits all" dosing is inappropriate for genetically variable drug metabolism.</p>
          </div>
        </div>
      </div>

      <div class="cough-medicine-history">
        <h4>ü§ß Cough Medicine Evolution</h4>
        <div class="cough-history">
          <ul>
            <li><strong>Early formulations:</strong> Simple codeine syrups for tuberculosis and bronchitis</li>
            <li><strong>Combination development:</strong> Addition of expectorants, antihistamines, decongestants</li>
            <li><strong>Pediatric concerns:</strong> Recognition of enhanced sensitivity and deaths in children</li>
            <li><strong>Abuse recognition:</strong> Transformation from medicine to recreational drug</li>
            <li><strong>Regulatory response:</strong> Restrictions on availability, prescription requirements</li>
            <li><strong>Alternative development:</strong> Non-opioid cough suppressants (dextromethorphan)</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Applications</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>üß¨ Pharmacogenetic Medicine</h4>
          <p>Ongoing research into CYP2D6 genetic testing for personalized codeine therapy. Studies focus on optimizing dosing based on metabolizer status and developing algorithms for individualized treatment approaches.</p>
        </div>
        
        <div class="research-item">
          <h4>ü§ß Antitussive Mechanisms</h4>
          <p>Investigation of codeine's cough suppression mechanisms beyond opioid receptors. Research explores optimal dosing for antitussive effects while minimizing abuse potential and adverse effects.</p>
        </div>
        
        <div class="research-item">
          <h4>üõ°ÔøΩEÔøΩEAbuse Deterrent Formulations</h4>
          <p>Development of tamper-resistant codeine formulations to prevent extraction and concentrated abuse. Focus on maintaining therapeutic benefits while reducing recreational potential.</p>
        </div>
        
        <div class="research-item">
          <h4>üè• Pediatric Safety</h4>
          <p>Continued research into safe pediatric use considering genetic variations. Studies examine alternative approaches for pediatric pain and cough management to avoid opioid-related risks.</p>
        </div>
      </div>

      <div class="clinical-applications">
        <h4>üè• Current Medical Applications</h4>
        <div class="medical-uses">
          <div class="medical-use">
            <h5>Mild to Moderate Pain</h5>
            <p>Primary indication for dental pain, post-operative pain, and chronic pain conditions where stronger opioids are not indicated. Often combined with non-opioid analgesics for enhanced efficacy.</p>
          </div>
          
          <div class="medical-use">
            <h5>Cough Suppression</h5>
            <p>Antitussive use for dry, non-productive coughs, particularly in conditions like bronchitis, pneumonia recovery, and cancer-related cough. Low doses effective for cough control.</p>
          </div>
          
          <div class="medical-use">
            <h5>Diarrhea Management</h5>
            <p>Off-label use for chronic diarrhea conditions, utilizing opioid constipating effects. Particularly useful in palliative care and certain GI disorders.</p>
          </div>
          
          <div class="medical-use">
            <h5>Addiction Treatment</h5>
            <p>Limited use in opioid addiction treatment as a mild substitute during tapering programs, though other medications are generally preferred for this indication.</p>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section addiction-treatment">
      <h3>üîÑ Addiction & Dependence</h3>
      
      <div class="addiction-profile">
        <h4>Dependence Characteristics</h4>
        <div class="dependence-factors">
          <div class="dependence-factor">
            <h5>‚ö° Physical Dependence</h5>
            <ul>
              <li><strong>Timeline:</strong> Physical dependence can develop within 1-2 weeks of regular therapeutic use</li>
              <li><strong>Tolerance:</strong> Analgesic tolerance develops over weeks to months</li>
              <li><strong>Withdrawal syndrome:</strong> Milder than stronger opioids but still clinically significant</li>
              <li><strong>Cross-dependence:</strong> Complete cross-dependence with other mu-opioid agonists</li>
            </ul>
          </div>
          
          <div class="dependence-factor">
            <h5>üß† Psychological Dependence</h5>
            <ul>
              <li><strong>Abuse potential:</strong> Moderate, lower than morphine but significant</li>
              <li><strong>Escalation patterns:</strong> Often progresses to stronger opioids</li>
              <li><strong>Combination abuse:</strong> Cold water extraction to concentrate codeine</li>
              <li><strong>Cultural factors:</strong> "Lean" culture increases recreational appeal</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="withdrawal-management">
        <h4>üîÑ Withdrawal Management</h4>
        <div class="withdrawal-approaches">
          <div class="withdrawal-approach">
            <h5>üíä Medical Tapering</h5>
            <ul>
              <li><strong>Gradual reduction:</strong> 10-25% dose reduction every 3-7 days</li>
              <li><strong>Combination considerations:</strong> Manage acetaminophen dependence separately</li>
              <li><strong>Symptom management:</strong> Clonidine, loperamide for withdrawal symptoms</li>
              <li><strong>Duration:</strong> 2-3 week taper for chronic users</li>
            </ul>
          </div>
          
          <div class="withdrawal-approach">
            <h5>üîÑ Opioid Substitution</h5>
            <ul>
              <li><strong>Buprenorphine transition:</strong> For patients with significant dependence</li>
              <li><strong>Methadone consideration:</strong> Rarely needed for codeine dependence alone</li>
              <li><strong>Dose conversion:</strong> Account for individual CYP2D6 status</li>
              <li><strong>Stabilization:</strong> Address underlying pain or cough conditions</li>
            </ul>
          </div>
          
          <div class="withdrawal-approach">
            <h5>üè• Outpatient Management</h5>
            <ul>
              <li><strong>Regular monitoring:</strong> Weekly appointments during tapering</li>
              <li><strong>Alternative therapies:</strong> Non-opioid pain management, cough alternatives</li>
              <li><strong>Psychological support:</strong> Counseling for underlying issues</li>
              <li><strong>Relapse prevention:</strong> Strategies for avoiding prescription drug abuse</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="prescription-abuse">
        <h4>üíä Prescription Drug Abuse Context</h4>
        <ul>
          <li><strong>Gateway opioid:</strong> Often first opioid of abuse due to easier access</li>
          <li><strong>Escalation risk:</strong> Frequently leads to stronger opioid use</li>
          <li><strong>Combination dangers:</strong> Acetaminophen toxicity with high-dose abuse</li>
          <li><strong>Social acceptance:</strong> Perceived as "safer" due to medical legitimacy</li>
          <li><strong>Prescription shopping:</strong> Seeking multiple prescriptions from different doctors</li>
          <li><strong>Internet sources:</strong> Online pharmacies and dark web availability</li>
        </ul>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.pharmacogeneticsgenome.org/">Pharmacogenetics Research Network</a> - CYP2D6 testing information</li>
          <li><a href="https://www.fda.gov/">FDA</a> - Codeine safety communications and warnings</li>
          <li><a href="https://www.cdc.gov/drugoverdose/">CDC Opioid Overdose</a> - Prescription opioid information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Addiction Support</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/find-help/national-helpline">SAMHSA Helpline</a> - 1-800-662-HELP treatment referrals</li>
          <li><a href="https://www.na.org/">Narcotics Anonymous</a> - Peer support meetings</li>
          <li><a href="https://www.suboxone.com/">Suboxone</a> - Buprenorphine treatment information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://www.narcan.com/">Narcan.com</a> - Naloxone access and training</li>
          <li><a href="https://getnaloxonenow.org/">GetNaloxoneNow.org</a> - Overdose prevention resources</li>
          <li><a href="https://harmreduction.org/">Harm Reduction Coalition</a> - Prescription drug harm reduction</li>
        </ul>
      </div>
    </div>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
    
    <!-- Only load interaction-checker.js on interaction checker page -->
    
</body>
</html>